Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Merck Sharp & Dohme LLC
Related studies linked through entity extraction aliases.
Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases
- Status
- TERMINATED
- Phase
- PHASE1
Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)
- Status
- TERMINATED
- Phase
- PHASE2
Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)
- Status
- COMPLETED
- Phase
- PHASE2
Window of Opportunity Study in Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
CMP-001 for Relapsed and Refractory Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative Treatment for Cervical Intra-epithelial Neoplasia
- Status
- COMPLETED
- Phase
- PHASE3
A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)
- Status
- COMPLETED
- Phase
- PHASE3
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
- Status
- COMPLETED
- Phase
- PHASE3
Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA
- Status
- COMPLETED
- Phase
- PHASE1
Combination Antiretroviral Therapy (cART) for PBC
- Status
- COMPLETED
- Phase
- PHASE2
A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Symptom-related Screening for Early Detection of CTEPH.
- Status
- COMPLETED
- Phase
- NA